Mark R. Wakefield

2.3k total citations
109 papers, 1.7k citations indexed

About

Mark R. Wakefield is a scholar working on Oncology, Immunology and Surgery. According to data from OpenAlex, Mark R. Wakefield has authored 109 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 32 papers in Immunology and 26 papers in Surgery. Recurrent topics in Mark R. Wakefield's work include Cancer Immunotherapy and Biomarkers (16 papers), Immunotherapy and Immune Responses (14 papers) and Immune Cell Function and Interaction (9 papers). Mark R. Wakefield is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Immunotherapy and Immune Responses (14 papers) and Immune Cell Function and Interaction (9 papers). Mark R. Wakefield collaborates with scholars based in United States, China and United Kingdom. Mark R. Wakefield's co-authors include Yujiang Fang, Ziwen Zhu, Qian Bai, Huaping Xiao, M. Nicholas Coppola, Jeffrey P. Harrison, Cynthia L. Russell, Richard Madsen, Jack T. Lin and Vicki S. Conn and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Urology and Cancer Letters.

In The Last Decade

Mark R. Wakefield

95 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark R. Wakefield United States	21	488	488	311	204	174	109	1.7k
Jeroen J. W. M. Janssen Netherlands	29	642 1.3×	419 0.9×	749 2.4×	148 0.7×	67 0.4×	142	2.9k
Imke H. Bartelink Netherlands	24	458 0.9×	246 0.5×	375 1.2×	212 1.0×	91 0.5×	64	1.9k
Félix Couture Canada	26	1.1k 2.3×	304 0.6×	491 1.6×	294 1.4×	183 1.1×	84	2.3k
W. Hallowell Churchill United States	22	266 0.5×	657 1.3×	381 1.2×	268 1.3×	40 0.2×	40	2.0k
Geoffrey A. Talmon United States	25	429 0.9×	189 0.4×	914 2.9×	216 1.1×	30 0.2×	127	2.3k
M. A. Mangues Spain	20	136 0.3×	139 0.3×	226 0.7×	86 0.4×	17 0.1×	49	1.0k
John S. Thompson United States	24	221 0.5×	529 1.1×	310 1.0×	101 0.5×	239 1.4×	86	2.0k
Richard L. Haspel United States	23	589 1.2×	652 1.3×	986 3.2×	85 0.4×	32 0.2×	75	2.4k
Changxi Wang China	23	318 0.7×	193 0.4×	372 1.2×	94 0.5×	490 2.8×	120	1.5k
Ryanne A. Brown United States	17	925 1.9×	710 1.5×	545 1.8×	186 0.9×	8 0.0×	64	2.0k

Countries citing papers authored by Mark R. Wakefield

Since Specialization

Citations

This map shows the geographic impact of Mark R. Wakefield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Wakefield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Wakefield more than expected).

Fields of papers citing papers by Mark R. Wakefield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Wakefield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Wakefield. The network helps show where Mark R. Wakefield may publish in the future.

Co-authorship network of co-authors of Mark R. Wakefield

This figure shows the co-authorship network connecting the top 25 collaborators of Mark R. Wakefield. A scholar is included among the top collaborators of Mark R. Wakefield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark R. Wakefield. Mark R. Wakefield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wakefield, Mark R., et al.. (2025). Leveraging Microorganisms to Combat Skin Cancer. Microorganisms. 13(2). 462–462. 1 indexed citations

Bruner, Janet, et al.. (2025). Mechanisms and Clinical Implications of Immune Checkpoint Inhibitors PD-1, CTLA-4, and TIM-3 in Cancer. 7(1). 20–29. 3 indexed citations

Wakefield, Mark R., et al.. (2025). Therapeutic frontiers in adrenocortical carcinoma: from standards to innovation. Medical Oncology. 42(8). 311–311.

Wakefield, Mark R., et al.. (2025). Promising immunotherapeutic treatments for colon cancer. Medical Oncology. 42(5). 175–175. 2 indexed citations

Burns, Cara C., et al.. (2025). From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer. Cancers. 17(7). 1135–1135.

Zhu, Ziwen, et al.. (2024). The Role of SARS-CoV-2 Spike Protein in the Growth of Cervical Cancer Cells. Anticancer Research. 44(5). 1807–1815. 1 indexed citations

Wakefield, Mark R., et al.. (2024). The Current State of the Diagnoses and Treatments for Clear Cell Renal Cell Carcinoma. Cancers. 16(23). 4034–4034. 4 indexed citations

Chen, Xuhui, Chenglu Qin, Christian J. Nelson, et al.. (2023). The Novel Use of IL-28 as an Effective Radiosensitizer in Pancreatic Cancer. Anticancer Research. 43(5). 1885–1890.

Bai, Qian, et al.. (2022). Ovarian Cancer Immunotherapy en Route: IL9 Inhibits Growth of Ovarian Cancer and Upregulates its Expression of Ox40L and 4-1BBL. European Journal of Gynaecological Oncology. 43(2). 163–163. 3 indexed citations

10.

Schneider, Theresa, Lei Zhao, Ziwen Zhu, et al.. (2022). The past, present, and future of immunotherapy for bladder tumors. Medical Oncology. 39(12). 236–236. 5 indexed citations

11.

Zhu, Ziwen, et al.. (2021). Targeting immunometabolism of neoplasms by interleukins: A promising immunotherapeutic strategy for cancer treatment. Cancer Letters. 518. 94–101. 6 indexed citations

12.

Sanders, Joyce, et al.. (2020). A Qualitative Assessment of Patient Satisfaction with Radical Cystectomy for Bladder Cancer at a Single Institution: How Can We Improve?. SHILAP Revista de lepidopterología. 2 indexed citations

13.

Zhao, Lei, et al.. (2019). IL-29 Exhibits Anti-Tumor Effect on Pan-48 Pancreatic Cancer Cells by Up-regulation of P21 and Bax. Anticancer Research. 39(7). 3493–3498. 9 indexed citations

14.

Russell, Cynthia L., Donna Hathaway, Debra Clark, et al.. (2019). Improving medication adherence and outcomes in adult kidney transplant patients using a personal systems approach: SystemCHANGE™ results of the MAGIC randomized clinical trial. American Journal of Transplantation. 20(1). 125–136. 32 indexed citations

15.

Zhu, Ziwen, et al.. (2018). Trichomonas Vaginalis Inhibits HeLa Cell Growth Through Modulation of Critical Molecules for Cell Proliferation and Apoptosis. Anticancer Research. 38(9). 5079–5086. 10 indexed citations

16.

Zhu, Ziwen, et al.. (2017). Beyond Conventional Medicine - a Look at Blueberry, a Cancer-Fighting Superfruit. Pathology & Oncology Research. 24(4). 733–738. 26 indexed citations

17.

Bryan, Christopher, Paul W. Nelson, Charles F. Shield, et al.. (2007). Long-Term Survival of Kidneys Transplanted from Live A2 Donors to O and B Recipients. American Journal of Transplantation. 7(5). 1181–1184. 21 indexed citations

18.

Wakefield, Mark R., et al.. (2000). Community beliefs about cancer treatment and care in South Australia. Cancer Forum. 24(1). 18. 3 indexed citations

19.

Rosenfeld, Ellie, Mark R. Wakefield, & L. Roberts. (1997). Smoking cessation among people with diabetes: beliefs and barriers. Health Promotion Journal of Australia. 7(1). 46. 5 indexed citations

20.

Roberts, L., et al.. (1997). Smoking behaviour, stage of change and preferences for cessation assistance among young people attending an institute of technical and further education (TAFE). Health Promotion Journal of Australia. 7(1). 18. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact